Adding elotuzumab to myeloma treatment decreases risk of disease progression
the ONA take:
The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced risk of disease progression or death by 30% in patients with relapsed or refractory multiple myeloma, according to a new study published online in the New England Journal of Medicine and presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, this week.
For the phase III ELOQUENT-2 trial, researchers randomly assigned 646 patients with relapsed or refractory multiple myeloma to receive lenalidomide plus dexamethasone with or without elotuzumab.
Results showed that after a median follow-up of 24.5 months, the 1-year progression-free survival rate was 68% in the elotuzumab group versus 57% in the control group. The 2-year progression-free survival rates were 41% and 27%, respectively. Researchers found that median progression-free survival was 19.4 months in the elotuzumab group compared with 14.9 months in the control group.
In regard to safety, the most common grade 3 or 4 adverse events in both groups were fatigue, lymphocytopenia, neutropenia, and pneumonia. In the elotuzumab group, 10% of patients experienced infusion-related reactions, of which the majority were grade 1 or 2.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|